Drug Trial Radar · NCT06126497
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Feb 5, 2024
Primary completion
Jul 19, 2024
Study completion Jul 19, 2024
Sponsor
- Lead sponsor
- Suven Life Sciences LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, parallel-group study to evaluate the safety and efficacy of Ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).
Conditions
- Major Depressive Disorder
Interventions
RopanicantDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse EventsTime frame: From Screening to Day 21
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Clinical Innovations, Inc
Bellflower, California
NRC Research Institute
Orange, California
Collaborative Neuroscience Research, LLC
Torrance, California
Innovative Clinical Research, Inc.
Miami Lakes, Florida
CenExel iResearch, LLC
Decatur, Georgia
CenExel iResearch, LLC
Savannah, Georgia
Precise Research Centers
Flowood, Mississippi
Neuro behavioral Clinical Research, Inc
North Canton, Ohio
Cedar Clinical Research, Inc.
Murray, Utah
Eastside Therapeutic Resource, Inc. dba Core Clinical Research
Everett, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.